Key Highlights:

In 2025, breast cancer treatment saw major advances in precision therapeutics, especially for patients with ESR1 mutations. New hormone treatments have shown compelling clinical efficacy.
Key Highlights:

  • Vepdegestrant (PROTAC SERD): In phase III trials for ESR1-mutant breast cancer, median PFS was 5.0 months vs 2.1 months with fulvestrant (HR = 0.57; P < 0.001) .

  • Camizestrant + CDK4/6 inhibitor: “Camizestrant with CDK4/6 inhibitors reduced the risk of progression or death by 56%.” 

Clinical Impact:

  • Camizestrant offers 16 months median progression-free survival, delaying the need for chemotherapy and improving quality of life 

  • Vepdegestrant shows a favorable safety profile, low severe adverse events (~8%) and manageable side effects 

Section

What You Should Do:

  1. Opt for ESR1 and PIK3CA mutation testing before beginning hormone therapy.

  2. Camizestrant paired with CDK4/6 inhibitors and monitored via ctDNA gives timely treatment adaptation.

  3. These novel SERDs can significantly delay chemotherapy, offering months of improved disease control.

Sources:

  • SERENA‑6 Trial (Camizestrant + CDK4/6): 56% reduced risk, HR+ ESR1-mutant advanced breast cancer 

  • VERITAC‑2 Trial (Vepdegestrant vs Fulvestrant): PFS 5.0 vs 2.1 months, HR=0.57, P<0.001